Rare genetic iron overload diseases are an evolving field due to major advances in genetics and molecular biology. Genetic iron overload has long been confined to the classical type 1 hemochromatosis related to the HFE C282Y mutation. Breakthroughs in the understanding of iron metabolism biology and molecular mechanisms led to the discovery of new genes and subsequently new types of hemochromatosis. To date four types of hemochromatosis have been identified: HFE-related or type1 hemochromatosis, the most frequent form in Caucasians, and four rare types, named type 2 (A and B) hemochromatosis (juvenile hemochromatosis due to hemojuvelin and hepcidin mutation), type 3 hemochromatosis (related to transferrin receptor 2 mutation), and type 4 (A and B) hemochromatosis (ferroportin disease). The diagnosis relies on the comprehension of the involved physiological defect ,that can now be explored by biological and imaging tools, which allow non invasive assessment of iron metabolism. A multidisciplinary approach is essential to support the physicians in the diagnosis and management of those rare diseases.
Introduction
Since the description of Hemochromatosis by Trousseau in 1865, and the demonstration of its genetic nature 1 , many studies have shed light on its putative pathophysiological mechanism. The first major breakthrough was the discovery of the HFE gene 2 . This made it possible to diagnose the most common form of hereditary hemochromatosis (HFE or Type 1 hemochromatosis) due to the p.Cys282Tyr mutation (C282Y) in the HFE gene.
Further discoveries unraveled iron metabolism regulation and its molecular mechanism, leading to the description of new and rarer form of hemochromatosis which are referred as non HFE hemochromatosis.
Hepcidin, which is coded by the HAMP gene 3 , plays a central role 4, 5 . Mainly secreted by the liver 6, 7 , this small peptide was shown to interact with ferroportin 8 (coded by the SLC40A1 gene), the only known cellular iron exporter, this interaction inducing ferroportin internalization and degradation. Thus, through its regulation of ferroportin, hepcidin can reduce iron export from macrophages and enterocytes into the bloodstream. The Transferrin Receptor 2 9,10 (TFR2, coded by the TFR2 gene) and Hemojuvelin [11] [12] [13] (coded by the HJV gene) are critical cofactors in hepcidin secretion regulation. Each of these genes can have mutation leading to different peculiar forms of Hemochromatosis, whose phenotypical expression can share common signs or have specific features. These discoveries, and the broader availability of genetic testing, enabled a better discrimination of HFE and non-HFE related Hemochromatosis from various secondary causes of iron overload. However, if physiology needs to be known for enlightening the expression of these conditions, it makes the diagnosis workup more complex since the phenotype can be mixed and the appropriate tests to perform difficult to choose. This emphasizes the relevant role of referral centers who can provide guidelines, genetic advice, and in-house genotyping testing to support physicians for proper evaluation of their patients with suspected rare genetic iron overload syndromes.
PHYSIOLOGY AND PATHOLOGY

IRON METABOLISM IRON UPTAKE AND EXPORT
Iron uptake occurs in the proximal part of the duodenum where two forms of iron are available: heme iron, mainly found in meat from the degradation of myoglobin and hemoglobin, and non heme iron found in vegetable and grains. Heme iron is carried out by endocytosis through the apical membrane of enterocytes, possibly by the Heme Carrier Protein 1 14 ; the subsequent catabolism pathways are not yet definitely demonstrated. Non heme iron is transported into the cytoplasm of enterocytes by Divalent Metal Transporter 1(DMT1) 15 . Ferroportin (SLCA40A1) [16] [17] [18] is the only known cell iron exporter, located at the basal membrane of enterocytes and at the membrane of macrophages, where it allows iron egress from the cytoplasm to the bloodstream with subsequent oxidation by hephaestin 19 and binding to transferrin ( Figure 1 ).
HEPCIDIN
Hepcidin (HAMP) is a small peptide, first identified as an antimicrobial peptide [4] [5] [6] . Mainly synthesized in the liver by hepatocytes, it is also produced at a lower level by adipocytes 20 and macrophages 21 . Highly expressed in iron overload and inflammation 4, 22 , hepcidin was later shown to be the key hormone of iron metabolism regulation 7, 23, 24 . Hepcidin interacts with ferroportin: circulating hepcidin binds to membrane ferroportin and causes subsequent ferroportin internalization and degradation 8 (Figure 1 ). As a consequence, cellular iron egress is impaired. Hepcidin causes hypoferremia by decreasing cellular release into the plasma 25 , therefore regulating body iron availability through influencing iron release by both enterocytes and macrophages.
HEPCIDIN REGULATION
The regulation of hepcidin expression has been mainly studied at a transcriptional level 26 . In inflammation, hepcidin induction results from the signaling of interleukin-6 through its receptor and STAT3 [27] [28] [29] [30] (signal transducer and activator of STAT3). Basal expression is regulated through a bone morphogenetic protein (BMP) /SMAD pathway 12, [31] [32] [33] . BMP6 34, 35 is thought to play a major role in association with its coreceptor hemojuvelin [11] [12] [13] (HJV), and is also involved in the response of hepcidin expression to iron stores 36 . Although molecular mechanisms remain not fully elucidated, it is currently accepted that HFE, TFR1, TFR2 and HJV form a complex at the hepatocyte membrane [37] [38] [39] , which is thought to play a major role in the sensing of iron stores according to serum transferrin saturation, with subsequent regulation of hepcidin expression 9, 40, 41 (Figure 1 ).
TFR2 has been reported to activate signal transduction involving MAP kinase pathway 42 . A post-traductional level of hepcidin activity control, which implicates the furin dependent cleavage process, has been recently highlighted 43, 44 .
IRON OVERLOAD
Iron overload arising from mutations in genes involved in iron metabolism are induced by two types of mechanisms HEPCIDIN DEFICIENCY Hepcidin deficiency is the key mechanism explaining iron overload in type HFE, HJV, HAMP and TFR2 related hemochromatosis. The corresponding mutations lead, through disturbances of signal induction cascades, to decreased hepatic synthesis of hepcidin. In HFE hemochromatosis it was demonstrated in mice and confirmed in humans that correction of liver hepcidin secretion normalized iron metabolism 45, 46 . Hepcidin deficiency leads to a sustained and unregulated activity of ferroportin with a double patho-physiological consequence 5, 47 .
On one hand, it leads to increased duodenal absorption of iron, and on the other hand, it enhances the release by macrophages into the blood of splenic iron originating from erythrophagocytosis. The overall result is increased plasma iron concentration associated to increased transferrin saturation. Beyond a certain level of transferrin saturation, peculiar biochemical iron species appear, named non-transferrin bound iron (NTBI) 48, 49 .
NTBI has the property to be very rapidly taken up by the liver 50 , pancreas and heart, and therefore produces parenchymal iron excess (namely hepatocytes for the liver). Moreover, an NTBI component, called labile plasma iron (LPI) 51, 52 , which appears whenever plasma transferrin saturation is over 75%, corresponds to a potentially damaging iron species due to its high propensity for generating reactive oxygen species.
IRON TRANSPORT ANOMALIES
The iron exporter Ferroportin can be involved in two types of diseases. In type A, mutations lead to a loss of activity of the protein 53 , and iron overload is related to decreased iron release from the macrophages as a consequence of functional deficiency. Conversely, in type B, the mutated ferroportin becomes resistant to hepcidin action 54 , thus despite an increased serum hepcidin level, the resulting "functional hepcidin deficiency" produces, through decreased ferroportin degradation, an increased ferroportin activity as in HFE hemochromatosis.
Mutations of the ceruloplasmin gene can hamper its ferroxydase activity (which transforms ferrous iron into ferric iron) which is mandatory for iron uptake by circulating transferrin after iron has been exported by ferroportin. As a consequence, excessive ferroportin degradation may occur, leading to decreased cellular export of iron 55 .
As one can see, in types HFE, HJV, TFR2, HAMP, and type B ferroportin hemochromatosis, cellular iron excess is due to an hepcidin deficiency with increased entry of excessive plasma iron into cells (predominantly parenchymal cells) whereas, in types A ferroportin disease and in hereditary aceruloplasminemia, cellular iron overload is related to decreased iron egress from cells with low circulating iron. These two different mechanisms have important implications both for the phenotypic expression of the diseases and for their therapeutic approaches.
ETIOLOGY
Actors of iron metabolism can suffer genetic alterations leading to perturbations of its physiological equilibrium. According to theinvolved genes and subsequent affected mechanisms, the phenotypes differ, thus dividing hemochromatosis in different subtypes.
HFE-RELATED (TYPE 1) HEMOCHROMATOSIS
HFE related hemochromatosis 56 is the classical, and first described form, of genetic iron overload. The HFE gene located on chromosome 6 codes for the membrane protein HFE, a MCH-Like protein whose definite role at the membrane remains unclear. Associated with β2-globulin, TFR1 and potentially TFR2 and HJV, it plays a critical role in iron load sensing to regulate hepcidin secretion 9, [37] [38] [39] [40] . However, the definite subsequent signaling cascade, although interacting with the BMP/SMAD pathway, remains to be determined. Alterations in the protein can eventually lead to a decreased and unregulated hepcidin secretion, promoting iron absorption and iron overload [57] [58] [59] [60] [61] . The paramount role of liver in this alteration of iron metabolism has been proven by its evolution after liver transplantation in humans 46 .
The most frequent and classical mutation of this gene is the p.Cys282Tyr (C282Y) mutation, which can lead to iron overload when present in the homozygous state 62 . The mutation prevalence is high in Caucasian populations 63, 64 (10% of the subjects are heterozygous, 3 to 5 subjects per thousand are homozygous), but almost absent in the non Caucasian populations 65 . Other genotypes than C282Y homozygosity cannot explain overt hemochromatosis : C282Y heterozygosity, H63D heterozygosity or homozygosity and compound heterozygosity C282Y/H63D do not result in clinically significant iron overload in the absence of cofactors accounting for disturbed iron metabolism (alcoholism or metabolic syndrome) 66, 67 . However some patients with compound heterozygosity C282Y/H63D may have, even without known cofactors, increased transferrin saturation and serum ferritin suggesting mild to moderate iron overload. Although they won't develop overt iron overload, and because many patients with C282Y homozygosity will also have only mild to moderate iron overload, the clinical relevance of compound heterozygosity is still debated. Moreover there is currently no data to define, biologically or clinically, what is a significant iron overload advocating for further diagnosis workup. Thus the role of compound heterozygosity in the diagnosis remains elusive in clinical guidelines 68, 69 .
Other rare (private) mutations of the HFE gene have been described associated to those frequent genotypes, thus explaining cases of iron overload 70 .
The phenotypic expression of C282Y homozygosity is quite variable, and the full-blown form of the disease (especially with cirrhosis) is rare [71] [72] [73] [74] . Given that C282Y homozygosity is necessary but not sufficient for iron overload development, the role of modifying factors, impacting iron metabolism or hepcidin secretion, has been advocated. These factors can be acquired (diet 75, 76 , alcohol 77, 78 , hepatic dysfunction 59 , metabolic syndrome 20, 79, 80 ), or genetic (gender-related 63, 64, 71, 81 or iron genes-related factors: well documented in mice [82] [83] [84] , the modifying role of associated genes of iron metabolism appears more mitigated in humans [85] [86] [87] [88] [89] ).
JUVENILE (TYPE 2) HEMOCHROMATOSIS
Described before the availability of genetic testing 90 [95] [96] [97] [98] [99] [100] [101] . Age of onset is usually described to be young adulthood (>30 years old) although several report of children with type 3 hemochromatosis do suggest that peculiar genotypes or cofactors could lead to more severe and earlier diseases 100, 102 . Cardiac and endocrine dysfunctions are less frequent than in juvenile hemochromatosis. Arthropathy is not rare. TFR2 is undoubtedly involved in hepcidin expression regulation, but its molecular mechanism remains unclear. TFR2 is complementary to HFE for hepcidin regulation according to iron load sensing 9, 40 . Moreover, TFR2 is supposed to interact with HFE at the hepatocyte membrane and may modulate the BMP/SMAP pathway through a cross talk involving the MAP/Erk signaling pathway 42 .
FERROPORTIN DISEASE -TYPE 4 HEMOCHROMATOSIS
This disease is due to mutations of the ferroportin (SLC40A1) gene located on chromosome 2 103, 104 . Unlike other types of hemochromatosis, inheritance is autosomal dominant. Although rare, it is more frequent than types 2 and 3 hemochromatosis and has been reported worldwide [105] [106] [107] . According to phenotypic expression it can be subdivided in two subtypes: i) Type A, the classical form, is characterized by normal or low transferrin saturation and liver biopsy shows macrophagic iron deposition ; ii) Type B variant which is more rare, is similar to types 1 and 3 hemochromatosis with elevated transferrin saturation and parenchymal iron deposition.
Overall, the clinical manifestations of ferroportin disease are limited 108 , with only seldom cases of liver damage reported which were frequently associated with cofactors. Liver damage may be more frequent in type B than in type A 109, 110 .
As afore-mentioned, Ferroportin is the only know iron exporter at the cell membrane. In type A ferroportin disease, mutations lead to loss of iron-export function and cause iron accumulation within macrophages accounting for the predominant spleen iron overload seen by magnetic resonance imaging. Theoretically trapped in the macrophages, iron biological availability is low explaining the normal or low transferrin saturation and the potentially lower tolerance to venesections than in HFE hemochromatosis. In type B ferroportin disease, mutations lead to resistance of ferroportin to hepcidin activity, resulting in an excessive cellular iron efflux. Thus, the phenotypic picture mimicks that of type 1 Hemochromatosis with increased serum iron and transferring saturation, and parenchymal iron deposition.
OTHER RARE IRON OVERLOAD DISEASES
Hereditary a(hypo)ceruloplasminemia is due to mutations of the ceruloplasmin gene 111 , which either totally inhibit protein production 112 or its ferroxidase activity 113 . Clinically, iron overload is associated with anemia and neurological symptoms. Other rare entities are presenting as anemia and iron overload syndromes: they are related to mutations of transferrin (atransferrinemia) 114 , DMT1 (Divalent Metal Transporter1) [115] [116] [117] [118] , X linked sideroblastic anemia (ALAS2 119 , ABC7 120 ) , or glutaredoxin 5 (GRLX5) genes 121 .
DIAGNOSIS WORK UP
The diagnosis work up of iron overload involves crucial steps to avoid misleading diagnosis due to confounding factors, and to optimize resource utilization. Many tools have been made available to help the physicians in this sequential strategy. Reference centers can ultimately be of primary importance to discuss difficult cases and assess the need for further specific explorations.
CAUSES OF REFERRAL, CLINICAL PRESENTATION
Clinical features associated with iron overload are diverse and can be more or less associated: asthenia, impotence due to endocrinopathy, arthropathy and osteopenia, skin darkening, hepatomegaly and moderate transaminase increase, diabetes, cardiomyopathy (cardiac failure or rhythm disturbance). However, due to improved knowledge of the disease and more widespread screening, the currently major cause of referral is elevated serum ferritin level, detected in the context of suspected iron overload, or uncovered during routine biological check-up or work up for other suspected diseases.
TO ASCERTAIN IRON OVERLOAD
The first step is to confirm that elevated serum ferritin is related to iron overload by assessing potential confounding factors, thus avoiding unnecessary explorations. This step is crucial and can be difficult as many frequent conditions can alter serum ferritin levels. Moreover, some of these causes can be associated with iron overload further increasing serum ferritin concentration.
CONFOUNDING CAUSES OF HIGH SERUM FERRITIN
ALCOHOL CONSUMPTION
Alcohol can increase serum ferritin levels by different direct means: alcohol itself can induce ferritin synthesis 122 , and inhibit hepcidin synthesis which can lead to mild iron overload 78 . 
METABOLIC SYNDROME
The definition of the metabolic syndrome initially suffered of controversy, but is now admitted to be 123 : Using the paramagnetic property of iron, Magnetic resonance imaging (MRI) is a fast and efficient non invasive technique to assess liver iron concentration 129, 130 . It requires an 1,5 Tesla MRI device (which is the most frequent) and the algorithm for iron evaluation proposed by the Rennes University is freely accessible on the website www.radio.univ-rennes1.fr.
A region of interest is drawn to compare the T2 signal between liver and paravertebral muscle, hyposignal (meaning dark liver as compared to paravertebral muscles), representing higher tissue iron concentrations. The very good correlation between hyposignal and hepatic iron overload allows to determine hepatic iron concentration with a satisfactory reliability. Moreover, it is highly relevant to evaluate hepatic versus an approximation of splenic iron load since a dominant splenic iron excess means preferential macrophagic iron deposition, therefore orientating the diagnosis towards transfusional iron excess or ferroportin disease 131 .
Alternative methods, using T2 relaxometry have been developed and are found to be more accurate to quantify liver iron content at all levels of iron overload 130, 132 . However due to hardware requirement and lack of standardization they are not yet widely available.
If MRI is not available or contra-indicated, liver biopsy, using Perls staining, remains a reference method for diagnosing iron excess 133 . Biochemical determination of iron concentration remains the gold standard.
Moreover, liver biopsy gives definite information regarding parenchymal or mesenchymal localization of iron overload which can be helpful in the diagnosis workup (review in Deugnier et al. 134 ). However, due to its invasive nature, morbidity, cost and the increasing place of MRI, liver biopsy is rarely needed for diagnosing the type of iron overload. Indications today are mainly to evaluate iron overload consequences in terms of hepatic fibrosis and to search for possible co-factors such as steatohepatitis (alcoholic or not (NASH)). Regarding fibrosis evaluation, there is growing evidence that non invasive procedures such as serum markers and/or transient elastography, can give relevant information 135, 136 .
PRIMARY OR SECONDARY IRON OVERLOAD
Once iron overload has been identified and quantified, its primary or secondary nature must be determined.
Oral supplementation, although rarely, can lead to iron overload 137 . It is thus necessary, through careful questioning, to ensure that the patient has not undergone prolonged iron supplementation. It is of major importance to assess this point in patient seeking sportive performance for professional 138 or non-professional reasons, as it has been considered that iron supplementation could increase hemoglobin status.
The main cause of secondary iron overload is represented by hematological conditions. Chronic or rare anemias such as thalassemia major, sickle cell disease, myelodysplatic syndromes, and congenital anemias, can be associated with iron overload.
Two, more or less associated, mechanisms can be involved:
-Increased iron load through repeated transfusions represents, a major cause of iron overload (each transfused unit provides 200-250 mg of iron so that significant iron excess develops after 10-20 units). This mechanism leads to an increased recycling of red blood cells process with enhanced iron deposition within macrophages, mainly in the spleen but also in hepatic Kupffer cells.
-Hepcidin deficiency. Ineffective erythropoiesis leads, through a yet not clearly defined pathway, to inhibition of hepcidin expression. The proposed role of Growth Differentiation Factor 15 139 is now questioned since a more direct link between erythropoiesis and hepcidin secretion has been recently reported. Indeed, a major breakthrough is represented by the discovery of the hormone named erythroferrone which corresponds very likely to the long-sought "erythropoietic factor" (Kautz et al, 2013, BioIron, London) . This could explain why iron overload can develop in chronic anemia, like thalassaemia, even in the absence of transfusions 140 , and why hepcidin expression is relatively low in those diseases despite transfusional iron excess (which should lead to increased hepcidin expression).
Past history of chemotherapy treatment should also be sought. Growth factor or sometimes multiple transfusions used in this context can also lead to iron overload. The long term outcome of "transitional" secondary iron overload is not known, but due to the absence of natural and effective iron elimination route, it is likely that iron overload can persist for years.
TO IDENTIFY THE GENETIC ORIGIN OF IRON OVERLOAD
Identification of the genetic cause of primary iron overload is driven by the combination of patient's clinical and biological data that suggest the possible underlying physiological mechanism.
A precise determination of the suspected disease is highly recommended as most of the genetic studies are not performed in routine and are both expensive and time consuming. Thus, a multidisciplinary approach is often required in complex cases and the help of referral centers should be sought.
As an example, in France, a national reference center, working in a nextwork with several regional competence centers, has been established (http://www.centre-reference-fer-rennes.org/) and proposes, on a weekly basis, multidisciplinary meetings where difficult cases are discussed in order to support physicians in their diagnosis work-up.
PATIENT AND FAMILY DATA
Patient's clinical and biological data have to be gathered through the initial phases of work-up. It should be emphasized that, due to important between and within-day variations of iron biological parameters (especially serum iron and transferrin saturation 141, 142 ), repeated measurements should be performed especially to avoid false positive results.
Family history is a major point to assess. Careful search for putative diagnosis of iron overload in relatives can suggest the presence of a dominant or recessive disease and strengthen the need for genetic exploration.
DECISION TREE
The decision tree is summarized in Figure 2 .
Serum transferrin saturation is the initial key point.
• Increased transferrin saturation 
MANAGEMENT OF NON HFE HEMOCHROMATOSIS
FAMILY SCREENING
Family screening is very important in the management of patients with genetic iron overload. It can provide precious clues in the diagnosis work-up of the patient but also help to determine if a genetic anomaly is a pathogenic mutation or a simple polymorphism by studying the genotype / phenotype correlations within the family. Mostly, family screening, following the diagnosis of a specific mutation in a given patient, allows earlier diagnosis thus preventing the development of iron-related organ damage related .
PHLEBOTOMY
The mainstay of treatment in genetic iron overload is removal of iron burden. Phlebotomies (venesections) remain the most efficient and convenient way to remove iron by forcing the bone marrow to use stored iron for intense erythropoiesis.
Treatment is performed in non-HFE hemochromatosis in a similar way to that of the type 1 form. The initial induction phase will remove the excessive iron and the maintenance phase will prevent its recurrence monthly as long as ferritin remains above the normal range, then fortnightly until the goal of 50µg/L is reached.
Once iron depletion has been achieved, the aim of maintenance treatment is to prevent recurrence of iron overload. Venesection is thus performed every 2-4 months to maintain a serum ferritin value close to 50µg/L. Special attention should be given to iron overload related to iron transport anomalies, like ferroportin disease, as anemia could occur more frequently. Therefore, hemoglobin levels should be closely monitored and phlebotomies should be performed initially less frequently to test for hematological tolerance.
OTHER THERAPEUTIC ASPECTS
DIET Although very commonly questioned by patients, and probably partially involved in the variable expression of the disease, no studies showed beneficial effect of dietary modification or alimentary iron avoidance in patient undergoing phlebotomy treatment. Thus, it is advised to maintain a healthy diet without stringent restrictions regarding iron. However, iron supplemented food should be avoided and it is usually recommended to limit vitamin C intake due to its possible toxic effect.
Special emphasis should be given to alcohol consumption. It has been clearly shown that, like in many liver diseases, excessive alcohol consumption increases liver damage 77 . Moreover, a direct inhibition effect of alcohol on hepcidin secretion favors iron overload.
ORAL CHELATION
Deferasirox (Exjade®) is an oral iron chelator, which, taken once daily, is used in post-transfusional iron
overload. An international study in HFE hemochromatosis showed satisfactory results regarding safety and efficiency 144 . Although off label, this treatment could be helpful in case of contraindication (anemia) or poor tolerance to phlebotomy. Moreover, it could be useful, in addition to venesections, in patients with massive iron overload and organ damage requiring very rapid removal of iron burden.
